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A B S T R A C T
The very slow progress in the therapeutic efficacy of the treatment of severe diseases has suggested the use of a
growing need for a multidisciplinary approach to the delivery of therapeutics to targets tissues. There has been
increasing effort in the design of stimuli-responsive nanomaterials that they will be developed into effective drug
delivery vehicles. Most commonly, effective drug delivery is associated with nanomaterial-facilitated accumula-
tion and/or cellular internalization. Recent studies in our lab have demonstrated that gelatin-based NPs can be
considered suitable pH responsive devices for the effective intracellular delivery of drugs.
Concerning cancer treatment, ligands recognizing tumour-associated antigens expressed on the surface of the
tumour cells have been employed. Some of the target structures suitable for tumour targeting belong to integrins
which mediate cell adhesion to extracellular matrix and other cells. Interestingly, gelatin chains contain motifs
such as RGD sequences that can be recognised by integrins.
In this work the inclusion of the anticancer drug 5-fluorouracil (5-FU) on these gelatin-based NPs has been
projected. These NPs may provide an opportunity to increase the therapeutic effect using a dual approach by: i)
targeting the therapeutic drug to the tumour cells by the action of the naturally occurring RGD-motif on gelatin
and ii) minimizing the non-productive trafficking from endosomes to lysosomes by releasing the cargo using the
charge reversal approach after cellular internalization. In vitro cytotoxicity experiments of NPs on tumoral and
non-tumoral cell lines have reported selectivity indexes higher than 30 demonstrating a great selectivity on the
mode of action as a function of the cell line and the imposed compositions.
1. Introduction
In recent years, there has been increasing effort in the development
of stimuli-responsive nanomaterials with the hope that they will be de-
veloped into effective drug delivery vehicles. These synthetic systems
utilize an assortment of endogenous or exogenous stimuli to induce a
variety of responses that can facilitate targeted drug delivery. Most com-
monly, effective drug delivery is associated with nanomaterial-facili-
tated accumulation and/or cellular internalization [1]. These stimuli in-
clude small molecules, proteins, nucleic acids, peptides, electron trans-
fer reactions, viscosity, osmotic pressure, and local environmental fac-
tors, such as pH, temperature, or redox state [2–5].
The advances in strategies for treating a wide variety of diseases re-
quire an efficient delivery of the active compounds into the cytosol of
target cells. One of the challenges for the efficient intracellular deliv-
ery of therapeutic biomolecules after their cell internalization by endo-
cytosis is to manipulate the non-productive trafficking from endosomes
to lysosomes, where degradation may occur. Recent studies in our lab
have demonstrated that the gelification properties of gelatin as well as
the strong dependence of gelatin ionization with pH makes this com-
pound an interesting candidate to be used to the effective intracellu-
lar delivery of active biomacromolecules. Gelatin B, which an isolectric
point (pI) of 4.8–5.2, is a negatively charged compound at physiolog-
ical pH. This property might be used to form nanoparticles (NPs) by
interaction with oppositely charged compounds, keeping the protective
structure until it enters into the cell. Once the particle enters the cell,
where the pH of the endosome would decrease until pH 5, gelatin B be-
comes positively charged, and due to electrostatic repulsion within pos-
itive charges the protection ceases and the entrapped drug can be re
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leased into the cell. This hypothesis has been recently used to the effec-
tive intracellular delivery of DNA and RNA [6,7].
In present scenario the management of cancer through drug thera-
pies often also results in deleterious effect on the normal healthy human
cells which can result in other adverse side reactions on different parts
of the body. The new area of focus in treatment of cancer is by admin-
istering drug by selective toxicity. Selective toxicity in simple terms can
be defined as the property of toxic substance to harm or kill a particular
species of cells (i.e cancer cells) without producing any harmful effect
to normal cells even if the two species are present in very close proxim-
ity [8].
For the improvement of cancer therapy, ligands recognizing tu-
mour-associated antigens expressed on the surface of the tumour cells
have been extensively employed. Some of the target structures suitable
for tumour targeting belong to integrins, a family of heterodimeric cell
surface receptors, consists of α- and β-subunits, which mediate cell ad-
hesion to extracellular matrix and other cells [9]. These cell surface re-
ceptors are universally expressed by tumour and normal cells. However,
the αV (especially αVβ3) are highly expressed on endothelial cells lin-
ing tumour and tumour cells but poorly expressed in resting endothe-
lial cells and most normal organs. The ligands that target these integrins
show the RGD motif. Interestingly, gelatin chains contain motifs such
as RGD sequences that modulate cell adhesion, thereby improving the
final biological behaviour over polymers that lack this cell-recognition
sites. Thus, gelatin-based NPs may provide an opportunity to increase
the therapeutic effect using a dual approach by: i) targeting the thera-
peutic drug to the tumour tissue without the harmful effects on the nor-
mal tissue by the action of RGD-motif and ii) minimizing the non-pro-
ductive trafficking from endosomes to lysosomes by releasing the cargo
using the charge reversal approach after cellular internalization.
Among the therapeutic drugs, 5-fluorouracil (5-FU) still remains the
only effective chemotherapeutic agent for the treatment of anal, breast,
colorectal, oesophageal, stomach, pancreatic and skin cancers [10].
5-FU acts in several ways, but principally as a thymidylate synthase (TS)
inhibitor [11]. However, primary and secondary resistance to 5-FU are
common phenomena in cancer chemotherapy [12].
In the present work, the preparation and physicochemical charac-
terization of 5-FU-based particles for the sustainable 5-FU delivery has
been described. The response of the NPs co-incubated in buffers at de-
fined pHs that mimic endosomal environments have been also deter-
mined. In vitro experiments have been performed in order to determine
the cytotoxicity and the patterns of cell death of the NPs on selected cell
lines.
2. Materials
Gelatin from bovine skin (gelatine type B) with gel strength 225 g
Bloom (GB225) and 75 g Bloom (GB75), protamine from salmon in the
sulphate salt (PS) and 5-Fluorouracil (5-FU) were purchased from Sigma
and used as received.
3. Methods
3.1. Preparation of proteins and 5-FU solutions
Solutions of gelatin type B were prepared by dissolution in PBS
pH 7.4 buffer. The concentration of the gelatin solution ranged from
5 to 20 mg/mL. Solutions of PS were prepared in PBS pH 7.4 buffer at
concentrations 0.1 and 1.0 mg/mL. 5-FU was dissolved in PBS pH 7.4
buffer (unless otherwise stated) with concentrations from 2.5 to10 mg/
mL. The maximum 5-FU concentration was established to 10 mg/mL,
due to its solubility limitations in aqueous solution [13].
3.2. Preparation of gelatin type B(5-FU) binary mixtures
5-FU was incorporated into the gelatin network when solutions of
gelatin type B and 5-FU, previously prepared in PBS pH 7.4 (unless oth-
erwise stated) were mixed at a ratio equal to 50% (v/v). Then, the ob-
tained mixtures were allowed in the refrigerator overnight, in order to
promote the gel formation.
3.3. Particle formation at the gelatin type B (5-FU)-protamine sulphate
system
Mixed gelatin (5-FU) systems (200 µL) were added dropwise into the
protein solution (2 mL) under vigorous stirring. The composition of 5-FU
in the mixed systems was fixed at 50% (v/v). Under optimal conditions,
droplets from the mixed gelatin (5-FU) systems broke under magneti-
cally stirring and instantaneously gelled into discrete particles on con-
tact with the cationic solution. For comparative purposes, particles in
the absence of 5-FU were also prepared.
3.4. Physicochemical characterization of the gelatin type B (5-FU)-
protamine sulphate nanoparticles (NPs)
3.4.1. Size and polydispersity
The size was determined by dynamic light scattering (DLS) at 25 °C
with a Zetasizer Nano ZS90. The size distribution was assessed from the
polydispersity index (pdI) that ranges from 0.0 for an entirely monodis-
perse sample to 1.0 for a polydisperse sample. The interpretation of data
was performed considering the size distribution by intensity of scattered
light [14].
3.4.2. Loading efficiency
In order to avoid some interference due to the NPs, the dispersions
were centrifuged at 10.000 rpm during 30 min. Then, the degree of 5-FU
entrapment in the NPs was determined by quantifying the free 5-FU in
the supernatant solution at 267 nm by means of a nanophotometer.
The degree of 5-FU entrapment is expressed through the loading ef-
ficiency values. Loading efficiency (LE) is calculated by comparing the
amount of 5-FU included in the NPs with the total amount during par-
ticle formation. Loading efficiency (LE) was determined with the equa-
tion:
Three batches of particles were prepared in each system and the re-
sults are given as average and standard deviations.
3.5. Effect of environmental acidification on the physicochemical properties
of gelatin type B (5-FU)-protamine sulphate system
Once the nanoparticle dispersions were formed at physiological pH,
two aliquots of 100 µL of 0.25 M HCl, were added in order to decrease
the pH until 5.0. The obtained dispersions were gently mixed and incu-
bated for 1 h. The effect of environmental acidification was measured
using the same parameters evaluated in Section 3.4.
3.6. Cell cultures
The murine Swiss albino fibroblast (3T3), the human epithelial carci-
noma (HeLa) and the human breast adenocarcinoma (MCF-7) cell lines
were grown in DMEM medium (4.5 g/L glucose) supplemented with
10% (v/v) FBS, 2 mM L-glutamine, 100 U/ mL penicillin and 100 µg/
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75 cm [2] culture flasks and were trypsinised using trypsin-EDTA when
the cells reached approximately 80% confluence.
3.7. Cytotoxicity assays
3T3 and MCF-7 cells (1 × 10⁠5 cells/ mL) and HeLa (5 × 10⁠4 cells/
mL) were seeded into the central 60 wells of a 96-well plate. After incu-
bation for 24 h under 5% CO⁠2 at 37 °C, the spent medium was replaced
in the wells with 100 µL of NPs system diluted 1:1 in fresh medium sup-
plemented with 5% FBS.
3.7.1. MTT assay
In this assay, living cells reduce the yellow tetrazolium salt MTT to
insoluble purple formazan crystals [15]. After cells were incubated for
24 h with the corresponding systems, medium was removed and 100 µL
of MTT in PBS (5 mg/mL) diluted 1:10 in medium without FBS and phe-
nol red was then added to the cells. The plates were incubated for a
further 3 h, after which the medium was removed. Thereafter, 100 µL of
DMSO was added to each well to dissolve the purple formazan product.
Plates were then placed in a microtitre-plate shaker for 10 min at room
temperature and the absorbance of the resulting solutions was measured
at 550 nm musing a Bio-Rad 550 microplate reader. The effect of each
treatment was calculated as the percentage of tetrazolium salt reduc-
tion by viable cells against the untreated cell control (cells with medium
only).
3.7.2. NRU assay
The NRU assay determines the accumulation of the NR dye in the
lysosomes of viable, undamaged cells [16]. Following exposure of cells
to the NPs, medium was removed and the NPs were incubated for 3 h
with NR dye solution (50 µg/mL) dissolved in medium without FBS and
phenol red. Cells were then washed with sterile PBS, following by the
addition of 100 µL of a solution containing 50% ethanol absolute and
1% acetic acid in distilled water to extract the dye. Agitation, determi-
nation of the absorbance of the extracted solution and effect of each
treatment measured at the same conditions that on 3.7.1. Section.
From the fitting of concentration-dependent viabilities curves, the
corresponding half-maximal inhibitory concentration (IC⁠50) values for
the different formulations were determined. The corresponding selectiv-
ity indexes toward cancer cells (either HeLa or MCF-7 cell line) were
calculated as the following ratio:
where 3T3 fibroblasts, one of the most common non-epithelial cell line
used in short- and long-term toxicological in vitro studies on cytotoxic-
ity and biocompatibility were used as closely representative of a physi-
ologic model cell line.
3.8. Statistical analyses
Experiments were performed at least three times on independent oc-
casions unless otherwise stated. Results are expressed as means standard
error of the mean (SEM). Data were analysed by PASW Statistics 18 soft-
ware using one-way analysis of variance (ANOVA) with Scheffé post-hoc
tests for multiple comparisons. Each experiment was performed at least
three times on independent measurements. Differences were considered
statistically significant at p < 0.05 or p < 0.005. In the figures signif-
icant differences were illustrated with asterisk (unless otherwise men-
tioned).
4. Results and discussion
4.1. Preparation of gelatin type B (5-FU)-protamine sulphate NPs at
physiological pH
The preparation of the gelatin type B (5-FU)-protamine sulphate NPs
consists of the dropwise addition of highly viscous gelatin type B (5-FU)
binary mixtures to protamine sulphate (PS) solutions with vigorous stir-
ring. In this series of experiments, three variables were considered: (i)
gel strength of gelatin type B (either 225 or 75 gel bloom) and gelatin
concentration (ranging from 2.5 to 10 mg/mL), (ii) PS (either 0.1 or
1.0 mg/mL) and (iii) 5-FU concentration (ranging from 1.25 to 5 mg/
mL). For comparative purposes, in all cases, NPs in the absence of 5-FU
were also prepared.
Fig. 1 summarizes the obtained results concerning the size and poly-
dispersity of the synthesized gelatin type B (5-FU)-PS NPs. Sizes ranged
from 200 nm to 400 nm, which make these NPs suitable systems for
the effective cellular internalization [17]. For a defined gelatin con-
centration, the size of the obtained NPs increases as the 5-FU concen-
tration goes up. Concerning the influence of gelatin gel strength, type
B225 might promote the formation of NPs with higher sizes than those
obtained with type B75. Regarding the polydispersity values, they re-
mained around 0.5, independently of the compositions (Fig. 1B). Similar
results were obtained for experiments carried out with PS concentration
at 0.1 and 1.0 mg/mL.
The degree of encapsulation of 5-FU on the proposed NPs was evalu-
ated by means of the loading efficiency parameter (Fig. 1C). The degree
of 5-FU entrapment can be modulated by varying both the gelatin type
B and 5-FU concentrations. LE values became minimal for gelatin con-
centrations equal to 2.5 and 5 mg/mL. For the highest gelatin concen-
tration (10 mg/mL), LE values varied exponentially between 0 and 8%
by increasing 5-FU concentrations from 1.25 to 5 mg/mL, in an almost
independent way of the gelatin gel strength (either B225 or B75). Sys-
tems prepared at 1.0 mg/mL PS induced slightly lower LE values.
4.2. Effect of pH on the preparation of gelatin type B (5-FU)-protamine
sulphate NPs
Studies carried out at physiological pH demonstrated limitations on
the encapsulation of 5-FU, with LE values lower than 10%. These val-
ues differ strongly of those obtained in the case of gelatin-based nu-
cleic acid-containing NPs [6,7]. Using both DNA from salmon testes and
three different RNA derivatives from torula yeast, NPs with LE values
higher than 80% were obtained. Differences on the effectiveness on
drug entrapment can be correlated with the physicochemical proper-
ties of the encapsulated drug. Thus, whereas DNA and RNA are both
highly dense negative macromolecules, 5-FU is a small molecule (MW:
130.08 g/mol) electrically neutral at physiological pH. For the former
derivatives, the interaction with the positively charged protamine sul-
phate is strongly favoured.
With the aim to promote a higher drug entrapment by increasing the
negative charge density of 5-FU, the pH of the PBS buffer was increased
until pH 8.4 considering its pKa value, 8.02. Electrostatic interactions
between oppositely charged compounds are the main driving force for
the self-assembly into the proposed NPs. At either pH 7.4 or pH 8.4,
gelatin type B (pI 4.8–5.2) acts as a negatively-charged polyelectrolyte
whereas protamine sulphate (pI 12) acts as a positively-charged protein.
Thus, it is expected that at this pH values, the ionic characteristics of
both gelatin type B and PS remained unaffected. However, changes on
the ionic density of 5-FU could be induced by modification of the pH of
PBS buffer from 7.4 to 8.4.
Fig. 2 shows representative results concerning size, polydispersity
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Fig. 1. Representative results on the particle size (A), polydispersity (B) and LE values (C) of gelatin type B (5-FU)-PS NPs at pH 7.4. The data correspond to the average of three indepen-
dent experiments ± standard deviation.
tions. Not evidence changes on the size of the NPs in comparison with
those obtained at pH 7.4 were detected. In a similar way of that ob-
served at physiological pH, NPs prepared with gelatin GB225 showed
bigger dimensions than those prepared with gelatin GB75. Concerning
NPs prepared with PS concentration equal to 0.1 mg/mL, the minimum
size values correspond to the systems containing the highest 5-FU con-
centration (5.0 mg/mL). For systems prepared at higher PS concentra-
tion, the NPs size result to be less sensitive to the effect of the 5-FU con-
centration. Fig. 2B summarizes the pdI values for the new gelatin type B
(5-FU)-PS NPs prepared at pH 8.4. In the view of the obtained results it
can be deduced that the increase in the pH value didn’t shown a strong
influence on the pdI values. In all cases, pdI values remained around
0.5–0.6.
The effect of pH 8.4 on the loading efficiency values is shown in Fig.
2C. The degree of encapsulated 5-FU strongly depends on the gelatin
concentration. Hence, for intermediate gelatin concentration (5 mg/
mL) the degree of 5-FU encapsulation exponentially decrease when the
5-FU concentration is increased, in an almost independent way of both
gelatin type B and PS concentrations. However, LE exponentially in-
creased as a function of the 5-FU concentration for either low or high
gelatin concentration. The maximum loading efficiency values (40%)
correspond to systems prepared at the highest gelatin concentration (ei-
ther 225 or 75) at the highest 5-FU concentration (5 mg/mL). The ef-
fect of gelatin type B concentration seems to be strongly modulated
by the incorporation of 5-FU as a function of 5-FU concentration, in a
fashion manner that seems to be dependent of the gelatin type B
strength.
In view of the influence of both gelatin type B and 5-FU concentra-
tion on LE values (Fig. 2C), the loading efficiency values of 5-FU on
the gelatin type B(5-FU) binary mixtures at both pH were determined.
Fig. 3A demonstrates that the incorporation of 5-FU on the gelatin type
B network for systems prepared at pH 7.4 was almost independent of
gelatin type B gel strength and concentration, and 5-FU concentration.
However, when binary mixtures were prepared at pH 8.4, the entrap-
ment of 5-FU is favoured, became maximum when both gelatin type B
and 5-FU concentrations are increased (Fig. 3B).
One of the most distinguished features of gelatin is the capacity to
form gels. The formation of these gels is strongly influenced by the
concentration and gelatin bloom values as well as the temperature of
the gel. The incorporation of 5-FU into the gelatin network was facil-
itated when dissolutions of gelatin type B and 5-FU, previously pre-
pared in PBS buffer, were mixed at a ratio equal to 50% (v/v). The
incubation of the binary mixtures at low temperature (approximately
10 °C) promoted the formation of gels for final gelatin type B concen-
trations ranged between 5 and 10 mg/mL. For binary mixtures prepared
at the lowest gelatin concentration (2.5 mg/mL), the formation of gels
could not be appreciated. This observation is consistent with the 5-FU
inclusion on both gelatin type B(5-FU) binary mixtures (Fig. 3) and
gelatin type B(5-FU)-PS NPs (Fig. 1C and C). In the case of interme-
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Fig. 2. Representative results on the particle size (A), polydispersity (B) and LE values (C) of gelatin type B (5-FU)-PS NPs at pH 8.4. The data correspond to the average of three indepen-
dent experiments ± standard deviation.
Fig. 3. Effect of gelatin type B concentration (ranged between 2.5 and 10 mg/mL) on the loading efficiency values of 5-FU on the gelatin type B (5-FU) binary mixtures at pH 7.4 (A) and
pH 8.4 (B). The data correspond to the average of three independent experiments ± standard deviation.
function of 5-FU concentration suggests limitations on the incorporation
of 5-FU on the gelatin network. This behaviour could be correlated with
some kind of electrostatically repulsion between both negative charged
compounds under the assayed conditions.
In view of the obtained results, NPs systems prepared in PBS pH 8.4
buffer at the highest gelatin type B (either 225 or 75) concentration
were selected as optimal conditions for carried out subsequent experi-
ments.
4.3. Effect of the environmental acidification
Since electrostatic interaction between oppositely charged com-
pounds is the main driving force for the self-assembly into these NPs, it
can be anticipated that a decrease in pH, as is occurring during endoso-
mal acidification, would influence the stability of the NPs. The decrease
of the pH would also lead to eventually release of 5-FU from the gelatin
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The effect of decrease from 8.4 to 5.0 (mimicking endosomal pH de-
crease) was evaluated as indicated in previous sections. A discrete in-
crease on size of around 100 nm could be observed by acidification from
extracellular to intracellular pH values, whereas pdI values reached lev-
els close to 0.8. These results were independent of all the studied condi-
tions. LE values strongly reduced once the pH was lowered. In all cases,
independently of gelatin type B gel strength, 5-FU and PS concentration,
LE values decreased until values close to 0 (Fig. SM1 A and B).
The effect of pH decrease from 8.4 to 5.0 was also verified in terms
of release the 5-FU (Fig. SM1C). The percentage of 5-FU released can
be slightly modulated from 95% to 100% for systems prepared at 5-FU
concentration equal to 5 and 2.5 mg/mL, respectively. No influence of
the PS concentration (either 0.1 or 1.0 mg/mL) on the amount of 5-FU
released was observed.
4.4. Cytotoxicity assays
4.4.1. In vitro cytotoxicity of pure components in solution
The increase of the biocompatibility and cytotoxicity of the NPs as
well as their starting products constitutes a key point on this research.
Previous studies in our lab have demonstrated that both gelatin type
B225 and gelatin B75 are non-cytotoxic compounds. It was possible to
establish the protein concentration required to inhibit cell growth by
50% compared with an untreated control (IC⁠50). This value can be de-
fined as higher than 2000 µg/mL for both gelatin type B for both 3T3
and HeLa cell lines. For PS, it was found to be 670 and 1250 µg/mL
for 3T3 (MTT and NRU, respectively) and 380 and 250 µg/mL for HeLa
(MTT and NRU, respectively) [6].
It is well-known that 5-FU, as a chemotherapy agent, is widely cho-
sen for the treatment of tumours. Some of its principal uses are in
colorectal and pancreatic cancer, in which it has been the established
form of chemotherapy for decades. It is sometimes of choice for the
treatment of the aggressive inflammatory breast cancer. When the cy
totoxicity of 5-FU has been considered, using non-tumoral 3T3 and tu-
moral HeLa cell lines, determined by MTT and NRU assays (Fig. SM2,
panels A and B) demonstrated that 5-FU in solution is non-cytotoxic,
even when very higher concentrations were assayed. Similar results
were obtained when the cytotoxicity assays were extended to the MCF-7
cell line, a human breast adenocarcinoma (Fig. SM2 C).
These results are consistent with those described in the literature,
which demonstrated that 5-FU presents the disappointing chemother-
apeutic effectiveness due to side effects and multiple drug resis-
tance [11]. Due to the high viability observed at the tested 5-FU concen-
tration range, the IC⁠50 has been defined as higher than 2000 µg/mL.
4.4.2. In vitro cytotoxicity of gelatin type B(5-FU)-protamine sulphate NPs
Once the relative viability of the isolated components was deter-
mined, the cytotoxic effect of the gelatin type B(5-FU)-PS NPs was eval-
uated. For comparative purposes, particles in the absence of 5-FU, and
5-FU in solution at the identical concentrations that those included in
the NPs were also tested.
The cytotoxicity results for gelatin-based 5-FU-containing NPs as a
function of the gelatin gel strength, 5-FU content and cell line are sum-
marized in Fig. 4, when MTT method was considered. A strong depen-
dence with the administration form on the cytotoxic responses was ob-
served. The responses induced by 5-FU in solution demonstrated that
for this dosage form, values close to 100% were obtained by the two
assayed concentrations, independently of the established cell line. Nev-
ertheless, when the interaction of GB225(5-FU)-PS NPs with cells was
considered, a strong dependence on the cell viability of the imposed
conditions was obtained. For NPs prepared at PS concentration equal
to 0.1 mg/mL, cell viabilities ranging between 10 and 170% were ob-
tained (Fig. 4A left). 3T3 and MCF-7 cells seem to be very sensitive
to cell proliferation, with viabilities equal to 140 and 170%, respec-
tively, for NPs prepared in the absence of 5-FU. For those prepared with
gelatin type B75, a similar trend was observed (Fig. 4A, right). Cell vi-
abilities ranged between 20 and 160%, being MCF-7 cells the most sen
Fig. 4. Effect of 5-FU concentration and gelatin gel strength (GB225, left and GB75, right) on relative viabilities of 3T3, HeLa and MCF-7 cell lines treated with gelatin type B (5-FU)-PS0.1
(A) and gelatin type B (5-FU)-PS1.0 NPs, in comparison with 5-FU in solution, for 24 h determined by MTT assay. The data correspond to the average of three independent experi-
ments ± standard deviation. Statistical analyses were performed using ANOVA followed by Scheffé’s multiple comparison test; *p < 0.05 and **p < 0.005 denotes significant differences
between cell lines, ⁠≠p < 0.05 and ⁠≠≠p < 0.005 denotes significant differences between NPs prepared in the absence and presence of 5-FU and ⁠●p < 0.05 and ⁠●●p < 0.005 denotes signifi-
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sitive to proliferation. Remarkably, for 5-FU-containing NPs, cell viabil-
ities ranged between 10 and 80%, in an almost independently of the
gelatin gel strength. Significant differences between NPs prepared in ab-
sence and presence of 5-FU were obtained in almost all cases. Addition-
ally, significant differences between NPS obtained in presence of 5-FU
and 5-FU in solution were found.
A similar trend was observed in the case of NPs prepared at the
highest PS concentration (Fig. 4B). The lowest cell viabilities values are
mainly associated to the cytotoxicity of PS [6]. For NPs prepared with
GB75, significant differences between NPs prepared in presence of 5-FU
and 5-FU in solution were found (Fig. 4B right). In the case of gelatin
GB225, these significant differences were only observed in the case of
HeLa cell line (Fig. 4B left).
Taking into account that the MTT assay is a measurement of cell
metabolic activity within the mitochondrial compartment [18], the ob-
tained results suggested that 5-FU in solution involve a poor interac-
tion with the mitochondrial compartment. However, the obtained re-
sults with gelatin-based NPs strongly suggested the uptake and internal-
ization mediated by the nanoparticulate system.
The NRU method demonstrated poor selectivity to discriminate be-
tween NPs or 5-FU in solution (Fig. SM3). Not significant differences
were found either between NPs prepared in absence or presence of 5-FU,
or 5-FU incorporated into the NPs and 5-FU in solution, independently
of the cell line. Cell viabilities ranged between 35 and 80% were ob-
tained. It is interesting to note that, in all cases, the cytotoxicity re-
sponses followed the trend: 3T3 > HeLa > MCF-7. It is well established
that the NRU assay measure the membrane integrity. NR dye diffuses
through intact cell membranes to accumulate within lysosomes [19].
The obtained results suggested that the plasma membrane and/or lyso-
somal compartments of the non-tumour cell line 3T3 seems to be more
sensitive to the deleterious effect of the assayed NPs or isolated com-
pounds in comparison of those observed in the case of the two tumour
cell lines. Among them, HeLa cells, however, were more susceptible
than MCF-7 cell line.For a successful drug delivery system, a selective
toxicity would be expected. Among the different types of cells, fibrob-
lasts are the most abundant in various tissues and play an important role
in wound healing, angiogenesis and tissue regeneration [20]. Results in
this work, concerning the cytotoxicity values of 3T3 fibroblasts incu-
bated in the presence of gelatin-based NPs (Fig. 4) suggest that these
gelatin-based carriers could be considered as promising materials for the
fibroblast adhesion and proliferation, as described in the literature [21].
Nevertheless, by incorporation of the corresponding antitumoral drug,
the increase on the cytotoxic responses, mainly on the tumoral cell lines,
would be found. Our results suggested that the required behaviour is
observed in almost all cases, for which the cytotoxicity of NPs prepared
in the absence of 5-FU became significantly lower than that observed
when encapsulated 5-FU was considered.
From the fitting of the concentration-dependent viabilities curves,
the corresponding concentration of gelatin type B (5-FU)-PS NPs, in
terms of the 5-FU concentration required to inhibit cell growth by
50%, compared with untreated control (IC⁠50) were determined. The ob-
tained results are summarized in Table 1. The IC⁠50 values of the corre
sponding systems demonstrated to be a function of both cell line and
endpoint method. In general, for the same cell line, MTT method
demonstrated to show less cytotoxic potency than that observed in the
case of NRU method. Thus, in the case of 3T3 cell line, IC⁠50 values are
higher than those determined by NRU method on three of the four sys-
tems. A similar trend was observed in the case of HeLa cell line. For
MCF-7 cell line, however, the opposite behaviour or not differences be-
tween endpoint methods were observed. From the IC⁠50 values can be
deduced that GB225 (5-FU)-PS0.1 and GB75 (5-FU)-PS1.0 NPs provide
the most and the less biocompatible systems, respectively.
The lack on cell viability where cell were incubated with NPs pre-
pared with PS equal to 1.0 mg/mL is mainly associated to the brief cy-
totoxicity of PS in solution, as has been previously reported [6]. Differ-
ences between nanoparticulate systems (either GB225 or GB75) for the
same PS concentration can be correlated with the capacity of the dif-
ferent protein systems to form weaker or stronger gelatin GB-PS com-
plexes. In the case of the GB-PS NPs, it was expected that the higher the
degree of complexation, the smaller the amount of protein that would
be released in solution, an amountwhich would be able to interact with
the cells and reduce their viability.
The observed differences on cell viability between nanoparticulate
systems (either GB225 or GB 75) could be related with discrepancies on
charge density as a function of gel strength. It has been noticed the rel-
atively high zeta potential of gelatin type B bloom 225 over gelatin type
bloom 75 which could be explained by the higher molecular weight of
the former and hence higher density of carboxylic groups at the surface
[22,23]
The superior efficacy of gelatin-based (5-FU)-containing NPs com-
pared to free 5-FU is in line with reports in the literature. Studies
demonstrated that the IC⁠50 value of noscapine-loaded GNPs on human
breast cancer cell line (MCF7) was significantly lower than that of free
noscapine.⁠24 Similarly, encapsulation of resveratrol into gelatin-based
NPs enhanced its anti-cancer efficacy against NCIH460 lung cancer
cells compared to free drug.⁠25 Cytotoxicity analysis of anti-cancer drug
loaded in gelatin-based NPs against different cancer cell lines showed
the higher anti-cancer activity compared to free drug which might
be attributed to greater endocytotic uptake of these NPs in cancer
cells [24–27]. From values on Table 1 can be deduced that SI seems
to be dependent on both the endpoint method and cell line type. In
the case of NRU method, any selectivity was detected, independently
of the cell line (either HeLa or MCF-7) and the NPs systems. In all
cases, SI values are always equal or lower than 1, demonstrating any
selectivity on the mode of action. By using the MTT method, the de-
gree of selectivity became dependent on both the cell line and the NPs
systems. When MCF-7 cell line is considered, only GB225 (5-FU)-PS1.0
NPs showed slightly selectivity, in comparison of that observed in 3T3
cell line. In the case of HeLa, SI values higher than 1 where obtained
for three of the four considered systems. Interestingly, in the case of
GB225 (5-FU)-PS1.0 NPs, SI value higher than 30 demonstrated that
this system exhibited a great selectivity for HeLa cell line, in compar-
ison with that observed for 3T3 cell line. From the obtained results it
can be deduded that the gel strenght of gelatin type B is a good factor
Table 1
Cytotoxic activities of the selected gelatin type B (5-FU)-PS NPs. The corresponding concentration (mg/mL) required to inhibit cell growth by 50% compared with untreated control (IC⁠50),
as a function of 5-FU concentration, have been determined. The selectivity indexes (SI) toward cancer cells were calculated as a ratio of the average IC⁠50 values for 3T3 fibroblast cells and






















GB225 (5-FU)-PS0.1 3.73 1.25 2.18 2.24 >5 >5 1.71 0.56 < 0.75 < 0.25
GB225 (5-FU)-PS1.0 1.84 0 0.06 0 1.43 4.4 30.16 1 1.29 n.a.
GB75 (5-FU)-PS0.1 >5 0 1.62 0 >5 >5 >3.08 1 1 n.a.
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on the mode of action of the nanoparticulate systems. As can be deduced
from Fig. 4 and Table 1, NPs prepared with the lowest gel strength
showed a poor selectivity between the assayed conditions than those ob-
served with NPs prepared with the gelatin type B of highest gel strength,
for which the highest SI values were obtained.
When cells are exposed to cytotoxic agents, there are various pat-
terns of cell death that they may undergo. The two major types of cell
death are apoptosis and necrosis. Necrosis is usually followed by an in-
flammatory response to the released cellular contents, often resulting in
further tissue damage [28]. Tumours with a high incidence of necrosis
rather than apoptosis show aggressive behaviour and generally have a
poor prognosis [29]. Other studies have also shown a relationship be-
tween the suppression of apoptotic cell death and subsequent tumour
progression in murine models [30–33]. Thus, the ability to distinguish
between these two modes of cell death, especially at very early time
points post-treatment, may provide useful information on the success of
treatment of cancer [28].
In order to determine whether these gelatin type B(5-FU)-PS
nanoparticles induced morphological alterations that could be attrib-
uted to one or another mechanism, the selected cells were incubated
in the presence of the nanoparticles and then stained with the nu-
cleic acid-binding fluorochromes AO and EB (Fig. SM4). These studies
were restricted to nanoparticles prepared at PS concentration equal to
0.1 mg/mL, due to the sharpest cytotoxic character of this protein at the
highest assayed concentration. Under the later conditions, cells showed
structurally normal orange-red nucleus as a consequence of the necrotic
process.
The untreated cells mainly exhibited a green fluorescence, due to
exclusion of EB but not of AO. Viable cells showed a light green nu-
cleus with intact structure and presented punctuate orange red fluo-
rescence in the cytoplasm, representing lysosomes stained by AO. Fol-
lowing treatment with gelatin-based nanoparticles, an increase in the
number of apoptotic cells has been revealed. Apoptotic cells with frag-
mented nuclei exhibited punctate or bubbly AO distribution in cytosol.
Apoptotic cells with a split nucleus and weak AO staining also exhibited
punctate or aggregated AO staining in the cytosol. The most significant
effects were observed with the treatments that were also the most cyto-
toxic in all the cell viability assays. For those cases, a slight to moderate
increase in the number of cells undergoing late apoptosis was observed.
These effects were 5-FU concentration-dependent, especially in the case
of HeLa cells incubated with gelatin type B75 (5-FU)-PS nanoparticles
(Fig. SM4).
5. Conclusions
The interaction between oppositely charged compounds has been the
basis for developing gelatin-based NPs by mixing solutions of gelatin
type B (either high or low gel strength) with solutions of protamine sul-
phate. The incorporation of 5-FU on the gelatin network was strongly
favoured by the increment on the negative charge density in 5-FU by
varying the pH from 7.4 (LE < 10%) to 8.4 (LE > 40%). As a function
of the imposed compositions, gelatin type B (5-FU)-PS NPs with sizes
ranged from 200 nm to 400 nm and pdI (0.4–0.5) were obtained, which
make these NPs suitable systems for the effective cellular internaliza-
tion. NPs co-incubated in buffers at defined pHs that mimic extracellu-
lar and intracellular environments have demonstrated that 5-FU can be
successfully released (95–100%).
A fast look on the in vitro cytotoxicity studies demonstrated the
strong influence of the endpoint method on the selectivity on the mode
of action. The cytotoxicity results determined by the NRU method seem
to be almost identical for NPs prepared in the absence and presence
of 5-FU, and those observed with 5-FU in solution. Hovewer, the MTT
method strongly discriminates between the action of 5-FU into the NPs
and 5-FU in solution. Taking into account that the MTT assay is a mea
surement of cell metabolic activity within the mitochondrial compart-
ment, the obtained results suggested that free 5-FU involve a poor in-
teraction with the mitochondrial compartment. Oppositely, the uptake
and internalization is strongly mediated by the nanoparticulated system.
Furthermore, following treatment with gelatin-based (5-FU)-containing
NPs, the increase in the number of apoptotic cells as revealed by FM
studies.
For a succesful biocompatible drug delivery system, any cytotoxic-
ity would be expected. Nevertheless, by incorporating the corresponding
antitumoral drug, the increase on the cytotoxic responses, selectively
target to the tumoral cell lines, would be expected. Our results demon-
strated that the required behaviour is observed, for which the cytotoxi-
city of NPs prepared in the absence of 5-FU became significantly lower
than that observed when encapsulated 5-FU was considered.
The determination of the IC⁠50 and de corresponding SI demonstrated
to be dependent onboth the endpoint method and cell line type. Thus,
whereas by the NRU method, any selectivity was shown, by using the
MTT method the degree of selectivity became dependent of both the
cell line and the NPs systems. Considering the influence of the cell
line, when MCF-7 cell line is considered, only GB225(5-FU)-PS1.0 NPs
demonstrate to show slight selectivity. For HeLa, SI values higher than
1 where obtained for three of the four considered systems. Interestingly,
SI values increased up to 30 for GB225 (5-FU)-PS1.0 NPs demonstrating
that this system exhibited a great selectivity for HeLa cell line, in com-
parison with 3T3 cell line.
The obtained results suggested that the proposed dual approach pro-
vides NPs with highly potent and selective non-toxic intracellular deliv-
ery properties. Current studies are focused on determining the acute in-
travenous toxicity of these NPs in vivo.
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